New Methods in Cardiovascular Biology
B oth human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) hold great promise in the field of regenerative medicine. [1] [2] [3] [4] [5] These cells are characterized by their indefinite self-renewing ability and pluripotent differentiation potential. Because these cells possess the ability to differentiate into all somatic cell types present in the human body, 6 in theory hESCs and iPSCs are ideal therapeutic donor sources, as exemplified by the recent first-in-human trial involving the transplantation of hESCdifferentiated retinal pigment epithelium (RPE) in patients with dry age-related macular degeneration and Stargardt's macular dystrophy. 7 However, further research has brought to light many issues regarding the direct delivery of these stem cells and their derivatives. Cell survival, teratoma formation, host immune rejection, and cellular migration outside the area of administration are among the most pressing challenges. [8] [9] [10] Thus, investigation into the in vivo behavior of transplanted cells is essential for both the full understanding of stem cells' therapeutic potential and their subsequent clinical applications.
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Molecular imaging has offered researchers an accurate, noninvasive, and sensitive means to longitudinally track in vivo cell behavior. [10] [11] [12] [13] [14] It has proven to be the most effective tracking modality for the study of cell survival and proliferation over time. In fact, reporter gene-based molecular imaging has been used to track teratoma formation, cell survival, and host immune rejection for both hESCs and iPSCs. [8] [9] [10] 15 However, clinical translatability of modified cells for reporter gene-based imaging has been hampered by current transgenesis methods using random integration, 16, 17 which is suboptimal for the following reasons: (1) The cell lines resulting from this method are nonisogenic, with some cells bearing single copies of the reporter gene, whereas others bearing multiple copies; (2) if the reporter genes are inserted into a closed locus or if 1 cell contains multiple copies, expression driven by the reporter genes tends to be unstable over time as a result of epigenetic effects 18, 19 ; and (3) it has been observed that insertional mutagenesis resulting from random integration can be severely detrimental to the biology of the stem cells. 20, 21 Imaging heterogeneous populations of these cells could lead to inaccurate assessment of in vivo cell behavior. Furthermore, from a clinical translation and regulatory perspective, batches of hESCs or iPSCs carrying a transgene at multiple random locations pose difficulties because the final product is biologically nonhomogeneous.
An added challenge in this regard comes from the use of transgenic hESCs and iPSCs for animal disease models as well as disease in a dish efforts. The development of iPSC technology has fostered great interest in understanding the impact that interpersonal genome variation has on phenotypic differences, and, consequently, large numbers of iPSC lines are being generated for that purpose. To allow a comparison of the iPSC in vitro and in vivo properties, reporter genes are indispensable, but it is essential to avoid the insertional effects of the reporter and the confounding effects of multiple reporter gene copies. Therefore, a safe targeted transgenesis method supporting long-term gene expression is vital to the translatability of molecular imaging for in vivo cell tracking. In the present work, we set out to develop a method to comprehensively solve this problem by using human genome editing. 22 This technology relies on an engineered zinc finger nuclease (ZFN) to induce a double-strand break, 23 which then allows targeted gene repair, 24 knockout, 25 or transgene integration. 26 Earlier work has established genome editing in hESCs and iPSCs. 27 Here, we wanted to investigate whether the ZFNs we developed for targeted gene addition to a genomic safe harbor 22 could be used to track the fate of hESCs and iPSCs in vitro and in vivo.
Classical work from the Soriano laboratory on the Rosa26 locus 28 prompted a complementary effort in human cells. The PPP1R12C gene on chromosome 19, also known as AAVS1, can be used as a landing pad for ZFN-directed transgenes to allow for their long-term expression.
22 AAVS1 is dispensable in hESCs and iPSCs when knocked out with either ZFNs 22, 29 or TAL effector nucleases (TALENs). 30 or made hemizygous by conventional gene targeting, 31 and also can carry transgenes in such a way that transcription of neighboring genes is not affected. 32 We reasoned that we could rely on genome editing to establish a method to rapidly generate isogenic hESC and iPSC panels carrying distinct reporters at the same genomic location.
The key aim of this study was to establish a platform for in vivo imaging of hESCs and iPSCs and their differentiated progeny. For this purpose, we introduced a reporter construct containing mRFP for FLI firefly luciferase (Fluc) for bioluminescence imaging (BLI), and herpes simplex virus thymidine kinase (HSVtk) for positron emission tomography (PET) imaging into the AAVS1 locus using ZFN-driven genome editing. Our results demonstrate that such ZFN-edited stem cells maintain long-term and robust reporter gene expression and can be accurately monitored by both BLI and PET imaging in live animals. Our data establish a turnkey method for rapidly generating isogenic hESCs and iPSCs carrying any number of reporter constructs for both in vitro and in vivo cell fate tracking.
Methods

Cell Culture and Maintenance of Human Pluripotent Stem Cells
For derivation of human iPSC line, see the Online Methods. Human ESCs (WA09; Wicell, Madison, WI) and iPSCs were cultured on Matrigel-coated plates (ES qualified; BD Biosciences, San Diego, CA) using mTeSR-1 cell culture medium (StemCell Technologies, Vancouver, Canada) under conditions of 37°C, 95% air, and 5% CO 2 in a humidified incubator, as previously described. 33 Cells were passaged via dissociation with collagenase IV (Invitrogen) every 4 to 6 days.
Construction of an AAVS1-TF Donor Plasmid for ZFN-Mediated Integration
The DNA fragment containing monomeric red fluorescent proteinFluc-HSVtk reporter genes was polymerase chain reaction (PCR)-amplified from the triple fusion (TF) construct (pFU-UFRTW) 34 with primers GGGGGGACATGTCAGCAGAGATCCA GTTTGGTT/ GGGGCGCGCCCCACATAGCGTAAAAGGAGCA and digested with restriction enzymes PciI and AscI (New England BioLabs). The fragment was then inserted into the MluI/NcoI cut site of the donor plasmid AAVS1-CAGGS-enhanced green fluorescent protein (eGFP) backbone (Addgene, Cambridge, MA). 22 The resultant donor plasmid, p5_AAVS1-SA-puro-pA-CAG-mRFP-Fluc-HSVtkpA-3_AAVS1 (referred to hereafter as AAVS1-TF), contains a splice acceptor element and a 2A linker placed in front of a promoterless puromycin-polyA cassette, which expresses the puromycin resistance element only if inserted downstream of a constitutively active promoter, such as the PPP1R12C promoter. The triple-fusion minigene cassette driven by the human ubiquitin promoter was placed downstream of the puromycin resistance element. 
Differentiation of Pluripotent Stem Cell-Derived Cardiomyocytes
Cardiomyocyte (CM) differentiation was performed following a protocol described by Laflamme et al, 35 with minimal modification. In brief, 2 × 10 6 undifferentiated ESCs were detached by Accutase (Sigma) and seeded onto Matrigel-coated plates (ES qualified; BD Biosciences, San Diego, CA) using mTeSR-1 cell culture medium for 1 day. To induce cardiac differentiation, we replaced mTeSR-1 medium with RPMI-B27 medium (Invitrogen), supplemented with the following cytokines: 100 ng/mL human recombinant activin A (R&D Systems) for 24 hours, followed by 10 ng/mL human recombinant Bone morphogenetic protein 4 (BMP4, R&D Systems) for 4 days. The medium was then exchanged for RPMI-B27 without supplementary cytokines; cultures were refed every 2 days for 13 additional days. Widespread spontaneous beating activity was typically observed by day 14 after addition of activin A. After 18 days of in vitro differentiation, cells were enzymatically dispersed for implantation using blendzyme IV (prepared at 0.56 U/mL in PBS; Roche) and DNAse (60 U/mL; Invitrogen) for 30 minutes at 37°C and enriched for CMs by separation over a discontinuous Percoll gradient.
Differentiation of Pluripotent Stem Cell-Derived Endothelial Cells
To derive ZFN-edited or unedited endothelial cells (ECs), we performed the differentiation protocol described by Li et al. 36 Briefly, we cultured undifferentiated hESCs in differentiation medium on Ultra-low attachment plates (Corning Incorporated, Corning, NY) for embryoid body (EB) formation. Differentiation medium consisted of Iscove's modified Dulbecco's medium with 16 BSA, insulin, transferrin (StemCell Technologies), 15% knockout TM serum replacement (Invitrogen, Carlsbad, CA), 2 mmol/L l-glutamine, 450 mmol/L monothioglycerol (Sigma, St. Louis, MO), 20 ng/mL basic fibroblast growth factor (bFGF), 0.1 mmol/L nonessential amino acids, 50 ng/ mL vascular endothelial growth factor (R&D Systems Inc), 50 mg/mL streptomycin, and 50 U/mL penicillin supplemented. Twelve days after differentiation, EBs were collected and resuspended in 1.5 mg/mL rat tail collagen type I (Becton Dickinson, San Jose, CA), then plated onto 6-well plates and incubated for 30 minutes at 37°C. On gel formation, each dish received an addition of EGM-2 medium (Lonza, Basel, Switzerland) with 5% knockout TM serum replacement, 50 ng/ mL vascular endothelial growth factor, and 20 ng/mL bFGF and was then further incubated for 3 days without media change.
Results
Rapid and Efficient ZFN-Mediated Targeted Reporter Addition Into the AAVS1 Safe Harbor Locus in hESCs
To overcome the limitations inherent in random integration of reporter genes, we designed a series of experiments to use ZFN technology for engineering human pluripotent stem cells for molecular imaging ( Figure 1A ). We designed a multifunctional reporter construct flanked by short (800 bp) stretches of homology to the ZFN target site 22 on chromosome 19 in exon 1 of the PPP1r12C gene ( Figure 1B) . A useful feature of this site is that it lies downstream of exon 1 of a transcribed gene 22 ; we therefore included a promotorless selectable marker in our donor construct to maximize efficiency of isolating the desired cell. 22 The reporter cassette, driven by the ubiquitin promoter, is a TF gene of mRFP, Fluc, and HSVtk supporting FLI, BLI, and PET imaging, respectively. 34 We introduced the reporter construct and the ZFN expression vector into hESCs (H9) by electroporation; after puromycin selection, 6 clones were screened by genomic PCR, all of which carried the transgenic cassette at the ZFN-specified location ( Figure 1C ). Bona fide-targeted addition was confirmed by Southern blotting on 4 single cellderived clones (designated as ZT1-4). As shown in Figure 1D , clones ZT2 and ZT3 carried the reporter cassette integrated on both copies of the AAVS1 locus, and clones ZT1 and ZT4 on 1 copy. Clone ZT1 also contained an additional randomly integrated reporter transgene. We also tested for the potential random integration of the ZFN expression plasmid with Southern blotting. The data revealed that there is no random integration of ZFN expression plasmid DNA in these edited cells (Online Figure IA) . We next genotyped a panel of putative ZFN off-target sites in clones ZT2-4 (Online Figure IB and IC) and the unedited allele of the AAVS1 in clone ZT4 (Online Figure ID and IE); our data demonstrate all to be wild type, in agreement with previous studies on the robust specificity of this ZFN set. 22, 29 In addition to the H9 line, we edited another hESC line, H7, using the same constructs. Successful integration of the reporter gene was confirmed by PCR (Online Figure IF) .
ZFN-Mediated Targeting of Human iPSCs
Next, we tested the ZFN integration system in iPSCs. To derive clinically translatable iPSCs, we generated several nonviral, transgene-free iPSCs using nonintegrating, episomal minicircle DNA vectors created in our laboratory. 37 The resulting iPSC lines expressed high levels of pluripotency markers and spontaneously formed 3 germ layers both in vitro at Stanford University on June 6, 2013 http://circres.ahajournals.org/ Downloaded from with EB formation and in vivo when injected into murine recipients (Online Figure IIA-IIC) . ZFN-driven targeted reporter addition to the AAVS1 locus was comparably efficient in the iPSCs (Online Figure IID) . We also edited 3 more iPSC lines generated in our laboratory with the TF construct and an iPSC line with cardiac-specific promoter myosin heavy chain driving eGFP reporter construct (Online Figure IIE) . The reporter gene addition was confirmed by PCR (Online Figure IIF) .
Preservation of Cell Pluripotency After ZFN Editing
To determine whether the genetic engineering and subsequent drug selection would affect stemness, we tested the pluripotency of our cells after ZFN editing and observed that all 3 ZFN-edited cell lines displayed normal morphology relative to control unedited H9 cells (Online Figure III) . Further testing revealed that ZFN-edited cells maintained their pluripotent state, as indicated by the expression of pluripotency markers Oct4, Tra-1-60, Sox2, Tra-1-81, Nanog, and SSEA4 ( Figure  2A ). Functionally, these cells were capable of differentiation into all 3 germ layers both in vivo ( Figure 2B ) and in vitro ( Figure 2C ). We also observed spontaneous EB beating after 2 weeks of differentiation (Online Video I). All ZFN-edited cells exhibited normal karyotypes ( Figure 2D ). Analysis of ZFN-edited iPSCs was also performed. These cells similarly maintained pluripotency, as demonstrated by pluripotency marker expression and EB formation (Online Figure IVA and IVB). In conclusion, both hESCs and iPSCs maintained their pluripotent potential after ZFN-mediated addition of reporter genes to the AAVS1 locus and subsequent drug selection.
In Vitro Imaging of ZFN-Edited Cells
To verify the functionality of the reporter genes in the ZFNedited stem cells, we tested the edited hESCs for expression of the integrated Fluc and HSVtk reporter genes. All 3 ZFNedited cell lines showed robust BLI and PET signals ( Figure  3A and 3B). Importantly, when ZFN-edited hESCs were First, reporter genes are integrated into AAVS1 locus using ZFN technology, and the specificity of the addition process is validated. Second, the pluripotency of ZFN-edited pluripotent stem cells (PSCs) is investigated. Third, the molecular imaging ability of ZFN-edited cells is tested both in vitro and in vivo. Finally, an application example of PSC-derived cardiomyocytes (CMs) and endothelial cells (ECs) is demonstrated. B, Schematic diagram of donor plasmid and endogenous AAVS1 locus after reporter gene addition. The donor plasmid contains a triple fusion reporter gene and a puromycin selection marker between 2 arms homologous to the targeting site, which is located in the first intron of PPP1R12C gene. ZFNs generate a double-strand break at the targeting site, which promotes homologous recombination. Reporter genes can insert into the AAVS1 locus by homologous recombination. Green boxes: the first 2 exons of PPP1R12C gene; pink box: the 2A ribosome stuttering signal; gray box: polyadenylation signal (pA); red arrow: primers used to detect targeted integration. Puro indicates puromycin resistance gene; Ubi, ubiquitin promoter; C, Detection of reporter gene addition by genomic polymerase chain reaction (PCR). All 6 clones screened are PCR positive, whereas the control cells that were only transfected with reporter construct (without ZFN expression constructs) are PCR negative. D, Southern blot analysis of gene addition shows that ZT1 and ZT4 clones contain single-copy-targeted integrations, whereas ZT2 and ZT3 clones contain targeted integrations into both AAVS1 sites. Clone ZT1 also contains a random integration. hESC indicates human embryonic stem cells; iPSC, induced pluripotent stem cells; Fluc, firefly luciferase; RFP, red fluorescent protein; HSVtk, herpes simplex virus thymidine kinase; and WT, wild type. differentiated into EBs, these EBs could still be imaged by BLI, demonstrating the retention of reporter gene expression after hESC differentiation ( Figure 3C ). As expected, ZFNedited iPSCs also showed robust Fluc enzyme activity as gauged by BLI (Online Figure IVC and IVD) . Finally, we demonstrated a strong correlation between the cell numbers and BLI signals ( Figure 3D and 3E) , validating the fact that Fluc signal intensity accurately represents the viable cell count. These results show that the quantity of ZFN-edited cells can be measured by BLI because the signal directly represents cell survival and proliferation. Similarly, we tested the activity of RFP for fluorescence imaging (Online Figure  VA) . In addition, we tested eGFP signal of the ZFN-edited a-myosin heavy chain (aMHC)-eGFP reporter cells. The edited iPSCs did not have eGFP signals at undifferentiated state (Online Figure VB) . However, during CM differentiation, the eGFP signals can be detected on day 11 (Online Figure  VC) . The CMs start beating on day 12 (Online Video II). In summary, we have established that ZFN-driven targeted reporter addition into the AAVS1 locus in hESCs and iPSCs produces pluripotent cells and differentiated progenies that are robustly compatible with fluorescence, bioluminescence, and PET imaging.
ZFN-Edited Cells Maintain Long-Term Reporter Gene Expression
The key to being able to track cell fate is long-term transgene expression on addition to the AAVS1 locus. To determine whether the multifunctional reporter cassette maintains its transcriptional status in the AAVS1 locus over an extended period, we measured reporter gene activity every 7 days for up to 8 weeks after having obtained and validated the genomeedited single cell-derived clones. BLI analysis revealed that luciferase enzyme activity remained constant through the duration of the experiment, indicating the stability of our reporter gene expression in the ZFN-edited cells ( Figure 3F and 3G) .
In Vivo Imaging of ZFN-Edited Cells
Next, we examined the in vivo imaging potential of the ZFNedited hESCs in mice. We injected 10 3 , 10 4 , 10 5 , and 10 6 hESCs into a subcutaneous site of each mouse and performed BLI on day 2. The results revealed that as few as 10 000 cells could be efficiently detected in vivo ( Figure 4A ). The cell numbers and bioluminescence signals were correlated in vivo ( Figure 4B ), consistent with our in vitro results ( Figure 3D and 3E) . These results confirm that ZFN-edited cells are accurate in tracing cell behavior in vivo. To examine whether ZFN-edited hESCs can also be imaged in vivo long-term. we performed at Stanford University on June 6, 2013 http://circres.ahajournals.org/ Downloaded from a teratoma formation assay in immunodeficient mice. We successfully monitored the teratoma formation until sufficient palpability for explantation (until week 6) via BLI ( Figure 4C and 4D). Therefore, the ZFN-edited cells and their derivatives are suitable for in vivo molecular imaging.
Molecular Imaging of Cardiomyocytes and Endothelial Cells Derived From ZFN-Edited ESCs
Myocardial infarction is the leading cause of death and morbidity in both industrialized and developing nations. Transplantation of cells, such as CMs and ECs, has shown promise as a strategy in the treatment of myocardial infarction. 36, 38, 39 However, the in vivo behavior of transplanted cells needs to be extensively investigated before clinical trials. To test the cardiovascular application potential of ZFN-edited cells, we first differentiated ZFN-edited hESCs into CMs (hESC-CMs) in vitro. We performed side-by-side comparisons of the ZFN-edited hESCs and unmodified hESCs for differentiation potential. After 12 days of differentiation, cell beating was observed for both ZFN-edited and unmodified hESC-CMs (Online Video III and IV). Both differentiation efficiency and cardiac marker expression (α-actinin, TNNT2, MLC-2a, and MLC-2v) in these ZFN-edited hESCs were similar to those seen in control unmodified hESCs (Online Figure VIA and VIB). Consistent with previous reports in hESCs and iPSCs, 40 ,41 3 types of action potential morphologies (nodal-like, atrial-like, and ventricular-like) were recorded from unedited and edited hESC-CMs (Online Figure VIIA) . The current-clamp mode recordings revealed no significant differences in action potential durations, action potential amplitudes, action potential durations at 90% repolarization, subpopulation ratio, or beating frequency between unedited and edited hESC-CMs (Online Figure VIIB-VIIF) . Similarly, we differentiated ZFN-edited cells into ECs (hESC-ECs). Flow cytometry results showed ≈97% pure population ECs from ZFN-edited cells, and ≈96% pure population ECs Figure VIIIA) . Morphogenesis, endothelial marker staining, angiogenesis potential, and DiI-ac-LDL uptake assays showed that ECs derived from ZFN-edited cells were also similar to those derived from control unmodified hESCs (Online Figure  VIIIB-VIIID) . These results demonstrate that the integration and expression of reporter genes from the AAVS1 locus do not influence the differentiation potential of hESCs.
Of further significant note, we show that 2 distinct differentiated cell types, CM and EC, generated from hESCs carrying a ZFN-directed transgenic cassette at AAVS1 are essentially indistinguishable from wild-type, unmodified, cells as gauged by a comprehensive panel of molecular and functional tests. We tested the imaging potential of these cells derived from ZFN-edited cells. As expected, both hESC-CMs and hESCECs showed robust luciferase signals by BLI in vitro ( Figure  5A-5D ). We then injected 1 million hESC-CMs or hESC-ECs into the mouse heart and imaged them in vivo. Robust luciferase signal was detected for both hESC-CMs and hESC-ECs in the heart up to 4 weeks after injection ( Figure 5E-5H) . The luciferase signal decreased over time as a result of donor cell death, consistent with results from our prior studies. 36, 38, 39 Overall, these results establish the applicability of ZFN-edited stem cells for preclinical in vitro and in vivo imaging studies.
Discussion
The present work aimed to use the latest genetic engineering techniques combined with in vitro and in vivo imaging applications to realize the full translational potential of hESCs and iPSCs. To our knowledge, this is the first application of ZFN genome editing technology for molecular imaging of hESCs and iPSCs. In this study, we successfully edited both hESCs and iPSCs using ZFNs and achieved a high efficiency of site-specific integration. We showed that both ZFN editing and reporter gene expression do not adversely affect cell pluripotency or differentiation potential for in vivo imaging applications. Furthermore, we demonstrated that over the extended period necessary for in vivo imaging, ZFN-edited cells robustly and stably expressed reporter genes without epigenetic silencing. Taken together, and in light of the recent advances in introducing stem cell progeny into the clinic, our data have important implications for the translational use of targeted genetic engineering.
First-generation transgenesis methods that rely on random integration are associated with substantial limitations. In this regard, we believe that ZFN-driven isogenic-targeted addition to a safe harbor is the preferred technology for basic science, preclinical, and in-the-clinic applications. 22, 29 Our data agree with reports demonstrating that the AAVS1 locus is nonessential for hESC/iPSC pluripotency 29, 31 and further establish that human stem cells carrying transgenes at this locus can be effectively imaged in vivo. We carefully compared, using a large panel of immunological, molecular, and cell physiological assays, the properties of unperturbed control cells and cells carrying a ZFN-directed transgene cassette at AAVS1. Both CMs and ECs transgenic at AAVS1 were indistinguishable from control nontransgenic cells in most aspects, other than being positive at Stanford University on June 6, 2013 http://circres.ahajournals.org/ Downloaded from for the transgene-encoding marker. Our data thus extend the existing data set on targeted gene addition to the AAVS1 locus 22, 29, 30, 42 to demonstrate its suitability for in vivo imaging. We built the reporter system not only to be multifunctional, but also to be compatible with a high-throughput process of engineering multiple distinct lines of hESCs and iPSCs. In our experiments, 100% of both hESC and iPSC single cellderived marker-positive clones carried the reporter at the ZFN-specified location. Accuracy and efficiency of this sort reduce the workload-associated with isolating desired cells, obtaining 1 single cell-derived clone per reporter construct, and validating the clones before proceeding with downstream studies to the theoretically possible minimum. This means that the method we describe can be applied to large panels of hESCs and iPSCs without a measurable detriment to process flow. It is also important that the genetic approach is highly specific. The within-cell action profile of ZFNs we have engineered is a function of their DNA recognition specificity. We investigated a total of 27 maximal-likelihood off-target cleavage sites for the ZFNs we used 29 and found all to be wild type. Our data thus add to the existing body of evidence validating the in-cell specificity of these ZFNs. 29, 43 Molecular imaging plays an important role in the tracking of stem cell fate in vivo, but conventional vectors that randomly integrate reporter genes throughout the genome are problematic and have limited applicability. In fact, variable expression levels among transduced cells and genetic silencing within the cells may occur depending on the integration site of the reporter gene. 31, 44, 45 Thus, the conventional reporter gene-based imaging may not truly demonstrate the behavior of cells. In this study, we successfully achieved long-term stable gene expression for up to 2 months by integrating the reporter genes into the AAVS1 locus (ie, in isogenic settings). Our observations in this regard are consistent with results from previous studies in both transformed and stem cells. 22, 29, 42, 45 Pluripotent stem cells are capable of indefinite self-renewal and pluripotency and show promise for cell replacement therapy. However, to fully understand the beneficial effects of pluripotent stem cell therapy, investigators must be able to track the biology and physiology of transplanted cells in living subjects over time. 46 In previous studies, we transplanted hESC-ECs and hESC-CMs into murine myocardial infarction models and monitored cell fate using molecular imaging methods. 36, 38, 39 However, the expression of reporter genes in these studies was achieved using a lentivirus system that could be silenced by epigenetic effects. To minimize the epigenetic influence, we made use of the ZFN-driven site-specific integration approach. CMs and ECs derived from ZFN-edited hESCs show no significant difference compared with those derived from unmodified ESCs, and the fate of these cells can be monitored in the heart over time. Application of this novel ZFN technology in the field of cardiovascular research can thus greatly accelerate the transition of findings from basic research toward clinical translation. In summary, our study has demonstrated that ZFN-driven addition of a reporter gene cassette is a powerful tool for modifying human pluripotent stem cells for molecular imaging.
What Is Known?
• Molecular imaging plays an important role in the characterization of stem cell behavior inside living organisms.
• Zinc finger nuclease (ZFN) technology bypasses the negative effects of current random genetic integration techniques.
• The AAVS1 locus is a safe harbor site in human genome and supports long-term transgene expression.
What New Information Does This Article Contribute?
• Use of ZFN to introduce the triple fusion reporter gene into the safe harbor AAVS1 locus for effective molecular imaging.
• Combines the latest genetic engineering techniques with state-of-theart in vitro and in vivo imaging applications to create a platform for investigating the translational potential of human embryonic stem cells and induced pluripotent stem cells.
Currently, most stable reporter gene expression is based on random integration, which is associated with unwanted insertional mutations and harmful effects on genetic expression, rendering this method problematic for clinical translation. The present work aimed to use the latest genome editing technique with molecular imaging applications to bypass these negative consequences and facilitate future translational potential of human embryonic stem cells and induced pluripotent stem cells. Using ZFN technology, we integrated a reporter gene complex into the AAVS1 locus of multiple pluripotent cell lines, injected these pluripotent cell progeny in mouse models, and tracked cell fate in vivo using bioluminescence imaging. We carefully compared these edited pluripotent cell lines and their derivatives, using a large panel of immunological, molecular, cellular, and physiological assays, with unmodified control cells to verify that our ZFN-modified cells are indistinguishable from control cells. Our data extend the existing data set on novel application of ZFN technology to targeted genetic engineering for molecular imaging of human pluripotent stem cells and their progeny. Genome editing on safe harbor sites may be a powerful technology for basic and translational research in cardiovascular sciences.
Novelty and Significance
SUPPLEMENTAL METHODS
Derivation of human iPSC lines.
For human iPSC generation, we followed the protocol developed by Jia et al. 1 Online Figure VIII at Stanford University on June 6, 2013 http://circres.ahajournals.org/ Downloaded from
